BACKGROUND: Primary Epstein-Barr virus (EBV) infection causes a spectrum of characteristics that range from asymptomatic seroconversion to severe infectious mononucleosis (IM), sometimes with prolonged symptoms and disability. We examined the relationships between clinical course, number of viral copies, and immunological parameters in a prospective cohort of subjects with recent IM. METHODS: Eight case patients with at least 6 months of disabling symptoms and 31 matched control subjects who had recovered promptly were included. Symptom scores were recorded at regular intervals over the course of 12 months. Cellular EBV load, EBV-specific antibody responses, lymphocyte subsets, and EBV-specific interferon (IFN)- gamma induction were measured. RESULTS: In case patients with prolonged illness, the severity of acute-phase symptoms was greater, the development of anti-EBV nuclear antigen-1 immunoglobulin G was more rapid, and the time to development of the peak IFN- gamma response to the majority of latent-cycle EBV peptides was generally slower than those in control subjects. However, in both groups, neither viral nor immune parameters correlated with the severity or duration of symptoms. CONCLUSIONS: The resolution of symptomatic IM is not determined by control of viremia, nor is it easily explained by altered host responses to EBV infection. The detailed determinants of delayed recovery remain to be elucidated.
BACKGROUND: Primary Epstein-Barr virus (EBV) infection causes a spectrum of characteristics that range from asymptomatic seroconversion to severe infectious mononucleosis (IM), sometimes with prolonged symptoms and disability. We examined the relationships between clinical course, number of viral copies, and immunological parameters in a prospective cohort of subjects with recent IM. METHODS: Eight case patients with at least 6 months of disabling symptoms and 31 matched control subjects who had recovered promptly were included. Symptom scores were recorded at regular intervals over the course of 12 months. Cellular EBV load, EBV-specific antibody responses, lymphocyte subsets, and EBV-specific interferon (IFN)- gamma induction were measured. RESULTS: In case patients with prolonged illness, the severity of acute-phase symptoms was greater, the development of anti-EBV nuclear antigen-1 immunoglobulin G was more rapid, and the time to development of the peak IFN- gamma response to the majority of latent-cycle EBV peptides was generally slower than those in control subjects. However, in both groups, neither viral nor immune parameters correlated with the severity or duration of symptoms. CONCLUSIONS: The resolution of symptomatic IM is not determined by control of viremia, nor is it easily explained by altered host responses to EBV infection. The detailed determinants of delayed recovery remain to be elucidated.
Authors: Barbara Anne Cameron; Carol R Emerson; Cassy Workman; Mark D Kelly; Andrew R Lloyd; Jeffrey J Post Journal: J Clin Immunol Date: 2011-09-20 Impact factor: 8.317
Authors: Wei Bu; Gregory M Hayes; Hui Liu; Lorraine Gemmell; David O Schmeling; Pierce Radecki; Fiona Aguilar; Peter D Burbelo; Jennifer Woo; Henry H Balfour; Jeffrey I Cohen Journal: Clin Vaccine Immunol Date: 2016-04-04
Authors: Ben Z Katz; Caroline Reuter; Yair Lupovitch; Kristen Gleason; Damani McClellan; Joseph Cotler; Leonard A Jason Journal: J Pediatr Date: 2019-03-08 Impact factor: 4.406
Authors: Ian Hickie; Tracey Davenport; Denis Wakefield; Ute Vollmer-Conna; Barbara Cameron; Suzanne D Vernon; William C Reeves; Andrew Lloyd Journal: BMJ Date: 2006-09-01
Authors: John Odame; Joan Robinson; Nasser Khodai-Booran; Simon Yeung; Tony Mazzulli; Derek Stephens; Upton D Allen Journal: Can J Infect Dis Med Microbiol Date: 2014-09 Impact factor: 2.471
Authors: Ben Z Katz; Simon M Collin; Gabrielle Murphy; Rona Moss-Morris; Vegard Bruun Wyller; Knut-Arne Wensaas; Jeannine L A Hautvast; Chantal P Bleeker-Rovers; Ute Vollmer-Conna; Dedra Buchwald; Renée Taylor; Paul Little; Esther Crawley; Peter D White; Andrew Lloyd Journal: Fatigue Date: 2018-01-19
Authors: Leonard A Jason; Joseph Cotler; Mohammed F Islam; Madison Sunnquist; Ben Z Katz Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 9.079